Replimune Group Inc · Q2 2021 earnings

Briefing

Reported fiscal second quarter financial results and provided a corporate update.

Replimune Group, Inc. announced financial results for the fiscal second quarter ended September 30, 2020, and provided a business update. The company released clinical data with RP2, demonstrating durable single agent responses in heavily pre-treated patients. Updated data for RP1 in combination with Opdivo in melanoma and non-melanoma skin cancers continues to improve upon the recent June update. The company closed on an offering of common stock and pre-funded warrants raising approximately $287 million.

• Updated deep and durable response data with Opdivo® in CSCC and anti-PD1 failed melanoma continue to support ongoing registration-directed development.
• Single agent deep and durable responses in heavily pre-treated patients with immune insensitive tumor-types demonstrates the potential of the platform to become the second cornerstone of immune-based cancer treatments.
• Regulatory clearance to initiate Phase 1 clinical development obtained.
• Raised gross proceeds of approximately $287 million through October upsized public offering; strengthened balance sheet allows for additional clinical trials, initial build of commercial infrastructure.

Headline financials

Revenue & EPS history

The company is well-financed to advance and expand its pipeline of product candidates and to fund the initial build of its commercial infrastructure. They look forward to initiating clinical development with RP3 as they seek to establish their products more broadly beyond immune-responsive tumor types, as a cornerstone of immune-based cancer treatments.